In terms of safety, as emerged from metanalyses [33], the spectrum of toxicities of ALK-TKIs differed, with anemia and constipation being more frequent with alectinib, whereas changes in lipid levels were the most frequent AEs associated with lorlatinib. This evidence concerns the gene ALK and anemia (phenotype).